LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

Robert J. Motzer, Paul Russo, Viktor Gruenwald, Y Tomita, B. Zurawski, Omi Parikh, S. Buti, Philippe Barthélémy, J.C.H. Goh, D. Ye, Alejo Lingua, J-B. Lattouf, Bernard Escudier, Saby George, Brian Shuch, Burçin Şimşek, J. Spiridigliozzi, A. Chudnovsky, A. Bex